MA52412A - Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie - Google Patents

Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie

Info

Publication number
MA52412A
MA52412A MA052412A MA52412A MA52412A MA 52412 A MA52412 A MA 52412A MA 052412 A MA052412 A MA 052412A MA 52412 A MA52412 A MA 52412A MA 52412 A MA52412 A MA 52412A
Authority
MA
Morocco
Prior art keywords
prophylaxis
derivatives
treatment
new
liver cancer
Prior art date
Application number
MA052412A
Other languages
English (en)
Inventor
Carina Hage
Sabine Hoves
Thomas Poeschinger
Carola Ries
Hong Shen
Hongying Yun
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA52412A publication Critical patent/MA52412A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA052412A 2018-02-28 2019-02-26 Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie MA52412A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2018077501 2018-02-28

Publications (1)

Publication Number Publication Date
MA52412A true MA52412A (fr) 2021-06-02

Family

ID=65685310

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052412A MA52412A (fr) 2018-02-28 2019-02-26 Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie

Country Status (19)

Country Link
EP (1) EP3758707A1 (fr)
JP (1) JP7089596B2 (fr)
KR (1) KR20200128414A (fr)
CN (1) CN111801100B (fr)
AR (1) AR114419A1 (fr)
AU (1) AU2019228654A1 (fr)
BR (1) BR112020016509A2 (fr)
CA (1) CA3091950A1 (fr)
CL (1) CL2020002139A1 (fr)
CO (1) CO2020010306A2 (fr)
IL (1) IL276817A (fr)
MA (1) MA52412A (fr)
MX (1) MX2020008746A (fr)
PE (1) PE20211456A1 (fr)
PH (1) PH12020551343A1 (fr)
RU (1) RU2020131012A (fr)
SG (1) SG11202008291XA (fr)
TW (1) TW202003518A (fr)
WO (1) WO2019166432A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
EA202091696A1 (ru) 2018-02-28 2021-01-27 Новартис Аг ПРОИЗВОДНЫЕ 10-(ДИ(ФЕНИЛ)МЕТИЛ)-4-ГИДРОКСИ-8,9,9a,10-ТЕТРАГИДРО-7H-ПИРРОЛО[1',2':4,5]ПИРАЗИНО[1,2-b]ПИРИДАЗИН-3,5-ДИОНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ РЕПЛИКАЦИИ ОРТОМИКСОВИРУСА ДЛЯ ЛЕЧЕНИЯ ГРИППА
KR102409595B1 (ko) 2020-06-29 2022-06-17 한국과학기술연구원 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
CN112420196A (zh) * 2020-11-20 2021-02-26 长沙市弘源心血管健康研究院 急性心肌梗死患者5年内生存率的预测方法和系统
CN119604517A (zh) * 2022-07-14 2025-03-11 豪夫迈·罗氏有限公司 用于治疗癌症的磷酰基嘌呤酮化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
BRPI1010937A2 (pt) * 2009-05-21 2019-09-24 Astrazeneca Ab composto, uso de um composto, e, método para tratar câncer
MX2012004706A (es) * 2009-10-22 2012-06-08 Gilead Sciences Inc Derivados de purina o deazapurina utiles para el tratamiento de (inter alia) infecciones virales.
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
WO2011163594A2 (fr) 2010-06-24 2011-12-29 Alkermes, Inc. Promédicaments de composés nh-acides : dérivés esters, carbonates, carbamates et phosphonates
RU2013110889A (ru) * 2010-08-13 2014-09-20 Бейлор Рисёч Инститьют Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки
CN107580596B (zh) 2015-05-08 2020-07-14 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的磺亚氨酰基嘌呤酮化合物和衍生物
SG11201802769RA (en) 2015-10-29 2018-05-30 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
PE20190476A1 (es) * 2016-08-29 2019-04-04 Hoffmann La Roche Compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica
CN109715214B (zh) * 2016-09-13 2022-03-04 豪夫迈·罗氏有限公司 Tlr7激动剂和hbv衣壳组装抑制剂的组合治疗

Also Published As

Publication number Publication date
CL2020002139A1 (es) 2021-01-04
TW202003518A (zh) 2020-01-16
AU2019228654A1 (en) 2020-09-03
JP7089596B2 (ja) 2022-06-22
JP2021514972A (ja) 2021-06-17
EP3758707A1 (fr) 2021-01-06
RU2020131012A (ru) 2022-03-28
PE20211456A1 (es) 2021-08-05
MX2020008746A (es) 2020-09-28
BR112020016509A2 (pt) 2020-12-15
PH12020551343A1 (en) 2021-06-21
CO2020010306A2 (es) 2020-08-31
AR114419A1 (es) 2020-09-02
CN111801100B (zh) 2023-10-24
WO2019166432A1 (fr) 2019-09-06
CN111801100A (zh) 2020-10-20
SG11202008291XA (en) 2020-09-29
CA3091950A1 (fr) 2019-09-06
IL276817A (en) 2020-10-29
KR20200128414A (ko) 2020-11-12

Similar Documents

Publication Publication Date Title
EP3947715A4 (fr) Procédés et compositions pour le traitement du cancer
EP3894392A4 (fr) Compositions et procédés pour le traitement du cancer
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
EP3641829A4 (fr) Promédicament d'interféron pour le traitement du cancer
EP3551185A4 (fr) Compositions et méthodes pour le traitement du cancer à médiation par cdk4/6
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA49906A (fr) Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
EP4085144A4 (fr) Compositions pour le traitement de l'ataxie de friedreich
EP3837359A4 (fr) Méthodes et compositions pour le traitement d'une maladie mitochondriale ou de troubles mitochondriaux et hétéroplasmie
EP3947460A4 (fr) Agents multispécifiques pour le traitement du cancer
EP3890749A4 (fr) Inhibiteurs de cdk9 et leurs polymorphes destinés à être utilisés en tant qu'agents pour le traitement du cancer
EP3883554A4 (fr) Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
EP3634431A4 (fr) Compositions et méthodes thérapeutiques pour le traitement de l'hépatite b
EP3478284A4 (fr) Composés et compositions pour le traitement du cancer
MA52961A (fr) Compositions et procédés pour la réduction ou le traitement d'une inflammation
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
EP3781584A4 (fr) Promédicaments de 4'-thio-nucléotide et de nucléoside pour le traitement du cancer
EP3723733A4 (fr) Méthodes et compositions pour le traitement du cancer utilisant des exosomes associés à l'édition génique
EP4149547A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3612214A4 (fr) Optimisation d'enzymothérapie de remplacement pour le traitement de l'homocystinurie
EP3817774A4 (fr) Compositions et méthodes pour l'administration locale d'agents pharmaceutiques pour traiter le cancer
EP3893902A4 (fr) Compositions et méthodes utiles pour le traitement du cancer colorectal d'aspect crénelé